Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Registration Number
- NCT04322591
- Lead Sponsor
- Hunan Province Tumor Hospital
- Brief Summary
This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus PD-1 antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer.
- Detailed Description
This study aims to explore the efficacy and safety of chemotherapy or chemotherapy plus the PD-1 antibody in RET Fusion Positive Advanced Non-small Cell Lung Cancer. We aim to enrolled 100 patients in this study, the primary endpoint was PFS.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
- ≥18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology
- RET Fusion Positive
- First Diagnosis and Treatment
- Treatment Plan is Chemotherapy or Chemotherapy plus PD-1 antibody
Exclusion Criteria
-
- Patients received antitumor treatment before
- Patients with contraindication of chemotherapy
- Pregnant or breast feeding women
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PFS may 2020- may 2021 (1 year) Progression free survival time
- Secondary Outcome Measures
Name Time Method ORR may 2020- may 2021 (1 year) Overal response rate
OS may 2020- may 2021 (1 year) Overall survival time
Trial Locations
- Locations (1)
Yongchang Zhang
🇨🇳Changsha, Hunan, China